Immunic's 2024 Achievements and Future Prospects

Immunic AG has provided an update on its progress and future plans. Key developments in 2024 include anticipated results from the Phase 2 CALLIPER trial in progressive multiple sclerosis (PMS) expected in April and positive interim results from Phase 3 ENSURE trials in relapsing multiple sclerosis (RMS). The company has also bolstered its leadership team with strategic hires.

Immunic has secured $80 million in the first of a three-tranche private placement, which is expected to extend its cash runway into Q3 2025. Vidofludimus calcium, their flagship drug, targets neuroprotective and anti-inflammatory pathways for MS.

The Phase 1/1b trial of IMU-856 showed promising results for treating celiac disease and was published in a reputable journal. These advancements underline Immunic's commitment to addressing unmet needs in chronic inflammatory and autoimmune diseases.